The Next Web

Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class

Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.

Aussie super funds hit the jackpot in $2b UK biotech deal

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...
The Manila Times

PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset

PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class ...
Agence France-Presse

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

Sofinnova Partners, a leading European life sciences venture capital firm, today announced that its portfolio company Myricx Bio (“Myricx”) has reached agreement to be acquired by Novartis, for up to ...
The Manila Times

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

Adds potential first-in-class,N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis ...

Open letter from Lula and Tedros: Preparing the next pandemic under capitalism

Within the framework of the imperialist crisis, data on pathogens and health responses are treated as strategic intelligence.